Incorrect. The stimulus only tells us about the FDA's role in introducing new therapies to the marketplace. We aren't told anything about what the FDA does after these therapies hit the market. So (A) may or may not be true, but we can't infer it from the stimulus.

Correct. By the contrapositive of the last sentence, we know that if a therapeutic agent is not transferred from the laboratory to the marketplace, it will not help patients. According to the stimulus, reaching the marketplace is a necessary condition for a therapy to help patients, so (B) is correct.

Incorrect. The stimulus never talks about an "excessively" long period for testing drugs. And though it is the research community that engages in the "long process" of testing, we don't know whose responsibility it is to set the duration of testing — the FDA could require a certain length of testing before it allows a therapeutic agent to hit the market. So we can't infer (C) from the stimulus.

Incorrect. The stimulus hasn't raised any concerns about the quality of therapeutic agents, and doesn't suggest any need for the FDA to work more closely with researchers.

Incorrect. This answer choice says that being transferred to the marketplace is a sufficient condition for a therapy to help patients:

transfer to market → help patients

But the last sentence of the stimulus said that being transferred to the marketplace was a necessary condition for a therapy to help patients, not a sufficient one. So (E) commits a sufficiency/necessity confusion and cannot be inferred from the stimulus.